New My NGC Tutorial Video
View the new My NGC Tutorial
on how to use the active and passive personalization features on the NGC Web site.
Health Awareness Topics - January 2013
- The Guidelines International Network North America (G-I-N NA) continues to sponsor a monthly webinar series on topics of interest to the North American guideline community. Information on upcoming webinars, as well as audio files and slides from past webinars, is available on the G-I-N Web site .
U.S. Food and Drug Administration (FDA) Advisory
- January 25, 2013: Samsca (tolvaptan) : Otsuka and FDA notified healthcare professionals of significant liver injury associated with the use of Samsca. Findings indicate that Samsca (tolvaptan) has the potential to cause irreversible and potentially fatal liver injury. Healthcare providers should perform liver tests promptly in patients who report symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice. If hepatic injury is suspected, Samsca should be promptly discontinued, appropriate treatment should be instituted, and investigations should be performed to determine probable cause.
NGC's Sister Resources